Therefore, these miRNAs have potential as new therapeutic biomarkers for BCR-ABL1 status in adult CML patients treated with TKIs at molecular responses. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.